Related Experiment Video
Updated: Aug 27, 2026
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 1, 2015
[Malignant mesothelioma--diagnosis and treatment strategies]
1Division of Respiratory Medicine, Dept. of Internal Medicine, Hyogo College of Medicine.
Abstract:
Malignant mesothelioma originates from the mesothelial cells of the pleural and peritoneal cavities as well as the pericardium and tunica vaginalis, which is a devastating neoplasm with a strong etiological relationship with asbestos exposure. The incidence is rising worldwide, with the peak incidence in most industrialized counties expected to occur in the year 2020. Given the disappointing results of the single standard therapeutic modality, the combination of extrapleural pneumonectomy, chemotherapy, and radiotherapy has been attempted in order to reduce local recurrence and distal spread. Combined modalities have a better prognosis in selected patients with epithelioid histology, clear resection margins, and no positive extrapleural nodes. Chemotherapy using new antimetabolite agents in combination with platinum compounds is useful for palliation and can improve both survival and quality of life compared with single-agent cisplatin.
Insights
Malignant mesothelioma, a cancer linked to asbestos, is increasing globally. Combined therapies like surgery, chemotherapy, and radiotherapy show promise for select patients, improving survival and quality of life.
Area of Science:
- Oncology
- Pathology
Background:
- Malignant mesothelioma is a rare and aggressive cancer originating from mesothelial cells.
- It has a strong association with asbestos exposure, and its incidence is rising worldwide.
- Current standard treatments offer limited efficacy, necessitating exploration of combined therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy of combined treatment modalities for malignant mesothelioma.
- To identify patient subgroups who may benefit most from aggressive therapeutic strategies.
- To assess the role of novel chemotherapy regimens in improving survival and quality of life.
Main Methods:
- Review of treatment outcomes for malignant mesothelioma patients.
- Analysis of combined modality treatments including extrapleural pneumonectomy, chemotherapy, and radiotherapy.
- Evaluation of chemotherapy regimens, focusing on antimetabolite agents and platinum compounds.
Main Results:
- Combined therapies demonstrate improved prognosis in selected patients with epithelioid histology, clear resection margins, and no positive extrapleural nodes.
- Chemotherapy with antimetabolite agents and platinum compounds offers palliation and improves survival and quality of life compared to single-agent cisplatin.
- The peak incidence of mesothelioma was anticipated around 2020 in industrialized nations.
Conclusions:
- Combined treatment modalities represent a promising strategy for managing malignant mesothelioma.
- Patient selection based on histological type and surgical margins is crucial for successful outcomes.
- Novel chemotherapy combinations can enhance palliation and improve patient outcomes in malignant mesothelioma.
